










Measurements:	 Regular	 use	 of	 sedative	 drugs	 determined	 according	 to	 the	 sedative	 load	10 
model,	 frailty	 phenotype	 status	 and	 frailty	 deficit	 index	 (FI)	 score	 assessed	 using	 validated,	11 
established	protocols.	12 
	13 








Conclusion:	 Higher	 sedative	 load	 was	 positively	 associated	 with	 phenotype	 frailty	 and	 the	22 












by	 the	 drugs	 used	 to	 treat	 them.2	 Older	 populations	 are	 often	 prescribed	 a	 range	 of	 drugs	with	34 
sedative	properties	(e.g.	psychotropics).3	Sedation	 is	defined	as	subjective	 feelings	of	drowsiness	35 
and	 sleepiness,	 but	 also	 as	 decreased	 psychomotor	 functioning,	 which	 can	 be	 measured	 in	36 
objective	 tests.4	 Sedative	drugs	have	been	associated	with	 falls,	 fractures,	physical	 and	 cognitive	37 
impairment	and	disability	among	community‐dwelling	older	people.3,5,6,7		38 
With	 more	 drugs	 being	 taken	 concomitantly,	 the	 risk	 of	 interactions	 and	 cumulative	39 
sedative	 effects	 is	 increased1,8,9,	 leading	 to	 the	 development	 of	 different	 models	 to	 study	 the	40 
sedative	 effect	 of	 drugs.10	 The	 “sedative	 load	model”	 was	 developed	 to	 quantify	 the	 cumulative	41 
effect	 of	 taking	multiple	 drugs	with	 sedative	 properties.11	Older age, female sex, lower education 42 
levels, impaired mobility depression and dementia are predictors of sedative load exposure. 3,8	43 
The	 global	 expansion	 of	 population	 ageing	 has	 lead	 to	 the	 clinical	 condition	 of	 frailty	44 
becoming	 an	 increasing	 challenge.	 Frailty	 develops	 as	 a	 consequence	 of	 age‐related	 declines	 in	45 
many	physiological	systems,	resulting	in	vulnerability	to	stressors	(e.g.	infection	or	hospitalisation)	46 
and	adverse	health	outcomes.12	Fried	et	al.13	characterised	frailty	as	a	clinical	phenotype	of	at	least	47 
three	of	 five	 indicators:	 unintentional	weight	 loss,	 slow	walking	 speed,	 self‐reported	exhaustion,	48 
low	 levels	 of	 activity	 and	 muscle	 weakness.	 Frail	 individuals	 are	 at	 increased	 risk	 of	 falls,	49 
hospitalisation,	worsening	mobility,	disability	and	death.12	Frailty	has	also	been	linked	to	impaired	50 
global	cognition	and	cognitive	decline.14,15	Using	a	different	approach,	Rockwood	et	al.16	have	also	51 
characterised	 frailty,	 as	 an	 age‐associated,	 non‐specific	 accumulation	 of	 deficits	 resulting	 in	52 
vulnerability	to	stressors	and	adverse	outcomes.	They	present	this	accumulation	of	deficits	as	an	53 
index	score	called	the	frailty	deficit	index	(FI).		54 
Frail	 older	 adults	 are	 more	 susceptible	 to	 age‐	 and	 disease‐related	 changes	 in	 their	55 
pharmacokinetic	and	pharmacodynamic	responses	to	drugs.2,17	This	is	compounded	further	as	frail	56 
individuals	are	more	likely	to	be	administered	several	medications,	resulting	in	polypharmacy..17,18	57 
In	 community‐dwelling	 older	 people	 living	 in	 Finland,	 higher	 sedative	 load	was	 associated	with	58 
  
poorer	physical	performance,	balance	and	mobility.19,20	 In	contrast,	higher	sedative	 load	was	not	59 
associated	with	poorer	physical	or	cognitive	performance,	but	was	associated	with	impairments	in	60 
activities	of	daily	living	(ADLs)	and	Instrumental	ADLs	(IADLs)	among	community‐dwelling	older	61 
men	in	Australia.8	Data	regarding	the	direct	association	of	sedative	 load	and	 frailty	has	not	been	62 
published.		63 











or	partner	was	 invited	 to	participate.	The	household	 response	 rate	was	62.0%.	Ethical	 approval	75 
was	 obtained	 from	 the	 Trinity	 College	 Dublin	 Research	 Ethics	 Committee	 and	 all	 participants	76 
provided	 written	 informed	 consent.	 Those	 with	 cognitive	 impairment	 	 that	 prevented	 consent	77 
being	given	were	not	 included	 in	 the	 study	 for	ethical	 reasons.	Participants	were	 interviewed	 in	78 
their	 homes	 and	 answered	 questions	 on	 health,	 social	 interactions,	 and	 financial	 circumstances.	79 
Each	participant	was	 invited	to	 travel	 to	a	health	centre	 for	a	comprehensive	health	assessment.	80 
The	sampling	procedure,	 the	home	 interview,	and	 the	health	assessment	have	been	described	 in	81 
detail	previously.21	From	the	total	sample	of	8,175	participants,	3,446	aged	65	and	older	provided	82 
details	of	their	regular	medication	use	(Tables	1	and	2).	Of	these,	1,718	participants	attended	the	83 
health	 centre	 assessment	 and	 provided	 sufficient	 data	 to	 assess	 their	 frailty	 status	 (Table	84 
3).Assessment	of	sedative	load	(SL)	score	85 
  
The	 in‐home	 inventory	 of	 drugs	 and	 food	 supplements	 was	 conducted	 by	 asking	 the	86 
question	“Now	I	would	like	to	record	all	medications	that	you	take	on	a	regular	basis,	like	every	day	87 
or	 every	 week.	 This	 will	 include	 prescription	 and	 non‐prescription	 medications,	 over‐the‐counter	88 
medicines,	vitamins,	and	herbal	and	alternative	medicines.”	No	 information	about	dose,	 frequency,	89 
quantity	or	prescription	status	was	obtained.			90 
Drugs	 were	 coded	 using	 the	 ATC	 (Anatomical‐Therapeutic‐Chemical)	 classification	91 
system22	and	the	effect	of	taking	multiple	drugs	with	sedative	properties	was	calculated	using	the	92 




and	 3‐4	were	 assigned	 sedative	 ratings	 of	 2,	 1	 (Table	 2)	 and	 0	 respectively.	 Sedative	 load	was	97 
calculated	 as	 the	 sum	 of	 the	 sedative	 ratings	 at	 an	 individual	 level,	 for	 regularly	 used	 drugs.	98 
Sedative	Load	(SL)	scores	of	0,	1‐2	and	3	indicated	no,	low	and	high	sedative	load	respectively.	99 
The	sedative	 load	model	was	 first	published	 in	2003	and	was	updated	 in	2011.3,11	 In	our	100 
study,	this	model	was	assessed	and	modified	to	 include	drugs	taken	by	participants	 in	this	study	101 
and	 to	 reflect	 the	 current	 knowledge	 about	 sedative	 effects	 of	 drugs.	 Two  experienced  clinical 102 
pharmacists  (IM,JP)  independently consulted,  reviewed and amended scores  for  the original updated 103 
list of drugs11	using standard and widely accepted reference sources e.g. product characteristics (SmPC) 104 
information,  and  Maudsley  Prescribing  Guidelines23.  Relevant  MEDLINE  articles  24‐26  informed  the 105 
scoring of drugs not included on the list.	Scores	were	reviewed	by	an	experienced	psychogeriatrician	106 








activity	 (sex‐adjusted	kilocalories	 (kcals)	 from	 the	 International	Physical	Activity	Questionnaire‐114 
Short	 Form	 [IPAQ‐SF]),	 and	 walking	 speed	 (sex‐	 and	 height‐adjusted	 cm/s	 using	 the	 GAITRite	115 
portable	 walkway)	 that	 made	 using	 the	 absolute	 cut‐points	 reported	 by	 Fried	 and	 colleagues	116 
inappropriate.	Weight	 loss	 was	 ascertained	 by	 the	 question	 “In	 the	 past	 year	 have	 you	 lost	 10	117 
pounds	(4.5	kg)	or	more	in	weight	when	you	were	not	trying	to.”	Exhaustion	was	captured	using	118 
two	 items	 from	 the	 20‐item	 Centre	 for	 Epidemiological	 Studies	 Depression	 (CES‐D)	 scale.		119 
Participants	were	asked	how	often	they	felt	that	“I	could	not	get	going”	and	“I	felt	that	everything	I	120 
did	 was	 an	 effort”.	 A	 response	 of	 “moderate	 amount/all	 of	 the	 time”	 to	 either	 question	 was	121 
considered	as	“exhaustion.”		The	presence	of	0,	1‐2	and	≥3	of	the	five	criteria	classified	participants	122 
as	non‐frail,	prefrail	(an	 intermediate	state)	and	frail,	respectively.	 	The	operationalization	of	 the	123 
frailty	phenotype	in	the	TILDA	cohort	at	Wave	1	has	been	described	previously.27,28		124 
Additionally,	 a	 frailty	 deficit	 index	 (FI)	 was	 constructed	 using	 40	 self‐reported	 health	125 
deficits	 from	 the	 TILDA	 home	 interview	 followed	 previously	 published	methodology	 (Appendix	126 
1).16,29	 The	 40	 deficits	 were	 associated	 with	 poor	 health,	 had	 a	 prevalence	 of	 5‐80%,	 were	127 
distributed	across	several	health	domains	and	were	associated	with	advancing	age.16	Each	deficit	128 




Demographics	 included	 age,	 sex,	 education	 (reference	 group:	 secondary/higher)	 and	133 
marital	 status.	 The	 health	 measures	 recorded	 were:	 self‐rated	 health	 (Ecellent/Very	134 
good/Good/Fair/	Poor);	disability	(the	inability	to	perform	one	or	more	Instrumental/Activities	of	135 
Daily	Living	(IADL	or	ADL))30,31;	falls	(≥1	self‐reported	fall	in	the	past	year);	the	number	of	chronic	136 
diseases	 or	 conditions	 (recorded	 as	 self‐reported	 physician’s	 diagnosis	 of	 heart	 attack,	 heart	137 
failure,	angina,	hypertension,	high	cholesterol,	stroke,	diabetes,	lung	disease,	asthma,	arthritis	and	138 




The	Center	 for	Epidemiologic	 Studies	Depression	 Scale	 score	≥16)33;	 anxiety	 (HADS‐A	 ‐	Hospital	142 
Anxiety	 and	 Depression	 Scale	 –	 Anxiety	 score	 	 ≥11)	 and	 loneliness.	 Life‐style	 factors	 included	143 
alcohol	consumption	(defined	as	a	yes/no	response	to	the	question	“Do	you	drink	alcohol?”)	and	144 
smoking	 status	 (defined	 as	 current/	 past/never	 based	 on	 two	 questions	 “Have you ever smoked 145 




Demographic,	 health	 and	 lifestyle	 measures	 were	 presented	 as	 means	 and	 standard	150 
deviations	 or	 counts	 and	 percentages.	 Comparisons	 across	 different	 SL	 and	 frailty	 groups	were	151 
conducted	 using	 chi‐square	 test	 for	 categorical	 variables	 and	 analysis	 of	 variance	 (ANOVA)	 for	152 
continuous	variables	including	SL	score	and	FI	score.		153 




											 Multivariate	 linear	regression	was	used	 to	determine	associations	between	 the	SL	and	FI	158 
scores.	 Unstandardized	 regression	 coefficients	 (B)	 with	 95%	 CI	 were	 measured	 with	159 











years	 group	 (0.51	 ±1.11)	 compared	 to	 those	 aged	 65‐74	 years	 (0.36	 ±0.93)	 or	 ≥85	 years,	 (0.48	170 
±0.97)	respectively;	p≤0.001.	Detailed	characteristics	of	this	cohort	by	SL	are	provided	in	Table	1.	171 
The	most	 frequently	 used	primary	 sedatives	 (Group	1)	were	hypnotics	 (ATC	N05C),	 and	172 
drugs	most	 used	 with	 sedation	 as	 a	 prominent	 side	 effect	 (Group	 2)	 were	 SSRIs	 (ATC	 N06AB)	173 





Of	 the	 3,446	 participants,	 1,718	 attended	 the	 health	 centre	 assessment	 and	 provided	179 
sufficient	 data	 to	 assess	 their	 frailty	 status.	 	 The	 prevalence	 of	 frailty	 in	 this	 sample	 was	 4.2%	180 
(n=72),	39.1%	(n=672)	were	prefrail	 and	56.7%	(n=974)	were	non‐frail.	 Frail	 participants	were	181 
significantly	older,	had	more	chronic	diseases,	poorer	education	and	more	I/ADL	disability.	They	182 
had	 significantly	 higher	 drug	 use,	 polypharmacy	 (5≥	 drugs)	 and	 sedative	 drugs	 use.	 Prefrail	183 
participants	 were	 an	 intermediate	 group	 performing	 significantly	 worse	 on	 these	 measures	184 
compared	with	the	non‐frail	group	but	significantly	better	than	the	frail	group.	Sedative	drug	use	185 
was	at	46%	for	frail,	23%	for	prefrail	and	9%	for	non‐frail	participants.	More	women	were	prefrail	186 






(OR	 1.63,	 95%CI	 1.43‐1.86)	 participants	 were	 significantly	 more	 likely	 to	 use	 medicines	 with	193 
sedative	properties	than	non‐frail	participants.	After	adjustment	for	all	listed	variables	in	Table	1,	194 
frailty	 (OR	1.30,	95%CI	1.02‐1.64;	p=0.023)	and	prefrailty	 (OR	1.27,	95%CI	1.11‐1.46;	p<0.001))	195 
  
remained	significantly	associated	with	SL	score.		196 











dwelling	 adults	 aged	 65+	 years.	 Our	 data	 indicates	 the	 use	 of	 sedative	 drugs	 was	 positively	208 
associated	 with	 being	 both	 prefrail	 and	 frail	 in	 unadjusted	 and	 adjusted	 analyses	 using	 two	209 
established	methodologies	to	assess	frailty,	phenotype	frailty	and	the	FI.		210 
Our	findings	revealed	that	one	 in	 five	participants	 in	our	study	took	at	 least	one	sedative	211 
drug,	which	falls	between	the	Australian	and	Finnish	studies	where	15	%	and	29%	of	participants	212 
reported	 sedative	 drug	 use,	 respectively.3,8	 These	 differences	 may	 emerge	 from	 age/sex	213 




differs	 from	 the	 Australian	 study8,	 where	 anxiolytics	 (Group	 1)	 and	 antidepressants	 (Group	 2)	218 
were	the	major	contributors	to	overall	SL.	We	updated	the	original	Finnish	model	to	reflect	current	219 










increase	 in	 SL	 score,	 the	 likelihood	 of	 being	 frail	 or	 prefrail	 increased	 by	 30%	 and	 27%,	229 
respectively.	While	a	clear	age	gradient	existed,	there	was	no	sex	difference	detected	in	our	sample	230 





and	 frailty	 may	 be	 explained	 by	 the	 adverse	 impact	 of	 sedative	 exposure	 on	 physical	 function,	236 
superimposed	on	a	sarcopenia‐related	frailty	process.	These	findings	could	have	important	clinical	237 




significant	 given	 their	 increased	 vulnerability	 to	 adverse	 drug	 reactions	 and	 adverse	 health	242 
outcomes.	Longitudinal	and	intervention	studies	with	measures	of	sarcopenia,	frailty	and	SL	may	243 
help	to	better	 inform	these	relationships.	 Indeed	additional	 future	waves	of	the	TILDA	study	will	244 
contribute	 to	 our	 understanding	 of	 the	 impact	 of	 increasing	 sedative	 load	 exposure	 among	 the	245 
prefrail	and	frail.		246 
Polypharmacy,	high‐risk	treatment	regimens	and	the	Drug	Burden	Index	(an	alternate	tool	247 
to	 the	 SL	model)	were	previously	 associated	with	 frailty	 at	 baseline	 and	 incident	 frailty	 after	2‐248 





and	 frailty.	 Furthermore,	 medication	 data	 was	 collected	 by	 trained	 interviewers	 in	 the	 home	253 
reducing	self‐report	recall	bias.39.	Few	methods	exist	to	measure	the	burden	of	sedative	drugs	but	254 





Drug	 dosage	 and	 frequency	 were	 not	 recorded.	 Only	 regularly	 taken	 drugs	 were	 included,	 not	260 
those	 taken	 ‘when	 required’	 (prn).	 There	may	 also	 be	 some	 limitation	 in	 terms	 of	 generalising	261 
findings	 in	 relation	 to	 the	 SL	 model,	 due	 to	 variations	 in	 the	 prescribing	 patterns	 of	 different	262 
countries	and	healthcare	systems.	To	provide	wider	generalizability	of	these	study	findings,	similar	263 
research	using	the	same	sedative	load	protocol	should	be	replicated	in	different	population.	 	The	264 
necessity	 to	 collect	 objective	 measurements	 of	 grip	 strength	 and	 walking	 speed	 in	 order	 to	265 
measure	 the	 frailty	phenotype	 status	 is	 also	a	potential	 limitation.	While	objective	measures	are	266 
considered	more	reliable	 than	self‐report	measures,	 they	are	often	 less	 feasible,	particularly	 in	a	267 
clinical	setting.	Indeed	participants	in	this	study	who	did	not	perform	a	health	assessment,	could	268 
not	 be	 assessed	 for	 frailty,	 although	 they	 were	 older,	 took	 more	 drugs,	 and	 had	 a	 higher	 SL.	269 
Similarly,	individuals	with	cognitive	impairment	that	prevented	informed	consent,	and	are	likely	to	270 
be	frail,	were	also	excluded	from	this	study.	 	This	suggests	that	our	estimation	of	the	association	271 
between	 sedatives	 and	 frailty	 may	 be	 conservative.	 Finally,	 cross‐sectional	 data	 do	 not	 allow	272 




The	 use	 of	 drugs	 with	 sedative	 properties	 in	 older	 Irish	 adults	 is	 significant	 and	 more	277 
prevalent	in	the	subpopulation	with	the	poorest	health	status.	In	this	study,	two	models	of	frailty	278 
  
were	 associated	 with	 higher	 SL.	 As	 frail,	 and	 prefrail,	 people	 are	 more	 susceptible	 to	 adverse	279 
responses	 to	 drugs	 and	 adverse	 health	 outcomes,	 additional	 consideration	 when	 choosing	280 
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Age	(Yrs)																					65‐74	 2,137	(62.0)	 1,771	(82.9)	 279	(13.1)	 87	(4.1)	
<0.001																																			75‐84	 1,091	(31.7)	 843	(77.3)	 172	(15.8)	 76	(7.0)	
																																				≥85	 218	(6.3)	 164	(75.2)	 44	(20.2)	 10	(4.6)	
Sex	(Female)	 1,804	(52.4)	 1,387	(49.9)	 310	(62.6)	 107	(61.8)	 <0.001
Education	(None/primary)		 1,514	(44.0)	 1,175	(42.3)	 255	(51.5)	 84	(48.6)	 <0.001
Married	 2,034	(59.0)	 1,708	(61.5)	 245	(49.5)	 81	(46.8)	 <0.001
Alcohol	users		 1,822	(63.1)	 1,516	(64.8)	 228	(55.9)	 78	(55.7)	 0.001	
Currently	smoking	 469	(13.6)	 357	(12.9)	 78	(15.8)	 34	(19.7)	 0.011	
No.	of	chronic	conditions	(Mean,	SD)	 2.21	(1.54)	 2.06	(1.46)	 2.76	(1.64)	 3.06	(1.87) <0.001
Self	rated	health	(Fair/Poor)		 564	(16.4)	 348	(12.5)	 152	(30.8)	 64	(37.0)	 <0.001
No.	of	drugs	(Mean,	SD)	 3.33	(2.71)	 2.79	(2.39)	 5.16	(2.60)	 6.86	(3.04) <0.001
IADL	disability	(≥1	disability)	 170	(4.9)	 121	(4.4)	 37	(7.5)	 12	(6.9)	 <0.001
ADL	disability	(≥1	disability)	 431	(12.5)	 262	(9.4)	 111	(22.4)	 58	(33.5)	 <0.001
Self	rated	memory	(Fair/Poor)	 705	(20.5)	 487	(17.5)	 153	(30.9)	 65	(37.6)	 <0.001
COPD/Asthma	 440	(12.8)	 319	(11.5)	 85	(17.2)	 36	(20.8)	 <0.001
MCI/Dementia	(MMSE score	≤24)	 245	(10.5) 175	(9.2) 50	(15.5)	 20	(15.7) <0.001
CVD	 1,993	(57.8)	 1,559	(56.1)	 319	(64.4)	 115	(66.5)	 <0.001
Arthritis	 1,304	(37.8)	 960	(34.6)	 241	(48.7)	 103	(59.5)	 <0.001
Stroke	 95	(2.8)	 53	(1.9)	 25	(5.1)	 17	(9.8)	 <0.001
Diabetes	 365	(10.6)	 276	(9.9)	 68	(13.7)	 21	(12.1)	 0.032	
Depression	(CES‐D	score	≥16)		 282	(8.4)	 165	(6.0)	 77	(16.0)	 40	(24.1)	 <0.001
Anxiety	(HADS‐A	score	≥	11)		 245	(9.0)	 157	(7.1)	 57	(15.2)	 31	(23.7)	 <0.001
Chronic	pain	(Moderate/severe)		 903	(26.2)	 591	(21.3)	 220	(44.5)	 92	(53.2)	 <0.001
Difficulty	sleeping	(Most	of	the	time)	 383	(11.1)	 245	(8.8)	 91	(18.4)	 47	(27.2)	 <0.001
Falls	(≥1	in	past	year)	 754	(21.9)	 551	(19.8)	 137	(27.7)	 66	(38.2)	 <0.001
Loneliness		














































Propulsives	 A03FA	 Domperidone		 21	 0.6%	
Anti‐Parkinson	Drugs	 N04	 biperiden,	ropinirole,	pramipexole,	rotigotine	 12	 0.3%	




Opioid	antitussives	 R05DA		 codeine,	dextromethorphan,	dihydrocodeine	 4	 0.1%	

























Frailty	Index	(FI)	score	(Mean,	SD)	 0.11	(0.08)	 0.18	(0.11)**	 0.32	(0.12)**	
Exposure	to	sedative	drugs	(SL	≥1)	 84	(8.6)	 153	(22.8)**	 33	(45.8)**	
Sedative	load	score	(Mean,	SD)			 0.17	(0.65)	 0.50	(1.05)**	 0.89	(1.22)**	
Age	(Mean,	SD)	 70.12	(4.44) 72.45	(5.56)**	 76.17	(6.59)**	
Sex	(Female)	 476	(48.9)	 361	(53.7)	 40	(55.6)	
Education	(none/primary)	 291	(29.9)	 237	(35.3)*	 30	(41.7)*	
Married	 719	(73.8)	 438	(65.2)**	 39	(54.2)**	
Rx	medication	exposure	 766	(78.6)	 584	(86.9)**	 71	(98.6)**	
No.	of	drugs	(Mean,	SD)	 2.53	(2.28)	 3.69	(2.74)**	 5.46	(2.89)**	
No.	of	chronic	diseases	(Mean,	SD)	 1.93	(1.37)	 2.39	(1.57)**	 3.60	(1.67)**	
Polypharmacy	(≥5	of	drugs)	 176	(18.1)	 236	(35.1)**	 39	(54.2)**	
IADL	disability	(≥1)	 13	(1.3)	 26	(3.9)**	 10	(13.9)**	
ADL	disability	(≥1)	 45	(4.6)	 89	(13.2)**	 29	(40.3)**	
Global	Cognitive	Function	(Mean	MMSE	score,	SD)	 28.41	(1.77) 28.00	(2.17)**	 27.08	(2.66)**	
Depression	(CES‐D	≥	16)	 26	(2.7)	 62	(9.5)	**	 21	(29.6)	**	





























































































Variable  Category  Prefrail Frail 
      Adjusted OR  [95% CI] 
p-
value 




Sedative load (SL) score [continuous variable] 1.31 (1.14-1.51) ≤0.001 1.43 (1.08-1.90) 0.014 
Age (years)          [continuous variable] 1.10 (1.08-1.13) ≤0.001 1.29 (1.21-1.37) ≤0.001
Depression [continuous variable] 1.08 (1.05-1.10) ≤0.001 1.17 (1.11-1.24) ≤0.001
Cognitive impairment  [continuous variable] 0.90 (0.84-0.96) ≤0.001 0.85 (0.74-0.97) 0.020 
Sex                 Male 1   1   
                        Female 1.16 (0.91-1.49) 0.229 0.96 (0.49-1.86) 0.901 
Education     Secondary or higher 1   1   
                      None/Primary 0.84 (0.65-1.08) 0.173 0.63 (0.31-1.27) 0.197 
CVD             No 1   1   
                          Yes 1.07 (0.85-1.35) 0.577 1.67 (0.77-3.60) 0.192 
Stroke              No 1   1   
                         Yes 2.83 (1.16-6.88) 0.022 7.22 (1.89-27.58) 0.004 
Diabetes       No 1   1   
                       Yes 2.07 (1.38-3.11) ≤0.001 1.95 (0.77-4.95) 0.159 
Arthritis         No 1   1   
                         Yes 1.20 (0.94-1.53) 0.150 2.05 (1.04-4.03) 0.037 
COPD/asthma        No 1   1   
                                Yes 0.94 (0.67-1.34) 0.749 1.32 (0.60-2.91) 0.490 
Smoking  Never 1   1   
  Current smoker 1.45 (0.96-2.19) 0.076 3.84 (1.40-10.55) 0.009 
  Past smoker 1.09 (0.85-1.40) 0.506 1.32 (0.63-2.76) 0.464 
Alcohol consumption     No 1   1   
                                       Yes 0.77 (0.60-0.99) 0.044 0.82 (0.41-1.64) 0.576 
BMI<18.5 and >30)           No 1   1   
         Yes 1.32 (1.03-1.69) 0.029 1.40 (0.70-2.82) 0.344 
Disability ADL              None 1   1   
  ≥1 ADL 2.23 (1.44-3.46) ≤0.001 4.14 (1.86-9.21) ≤0.001
  ≥1 IADL 2.15 (0.99-4.64) 0.052 7.07 (2.12-23.55) 0.001 
Self-rated health      
Excellent/Very 
good/Good 1   1   
  Fair/Poor 2.54 (1.63-3.94) ≤0.001 11.90 (5.52-25.66) ≤0.001
Loneliness     None of the time 1   1   










Variable Category Prefrail Frail 
    
Adjusted OR 
[95% CI] 
p-   
value 




Sedative load score [continuous variable]  1.35 (1.16-1.56) ≤0.001 1.49 (1.10-2.01) 0,010 
Age (years)          [continuous variable]  1.10 (1.08-1.13) ≤0.001 1.29 (1.21-1.37) ≤0.001
Depression [continuous variable]  1.08 (1.05-1.10) ≤0.001 1.17 (1.11-1.23) ≤0.001
Cognitive impairment [continuous variable]  0.90 (0.84-0.96) ≤0.001 0.85 (0.74-0.98) 0,021 
Sex Male  1   1   
         Female  1.16 (0.91-1.48) 0,242 0.96 (0.49-1.86) 0,891 
Education       Secondary or higher  1   1   
                   None/Primary  0.84 (0.65-1.09) 0,181 0.63 (0.31-1.28) 0,202 
CVD            No  1   1   
  Yes  1.07 (0.85-1.36) 0,558 1.68 (0.78-3.62) 0,188 
Stroke        No  1   1   
  Yes  2.83 (1.16-6.89) 0,022 7.20 (1.88-27.54) 0,004 
Diabetes      No  1   1   
  Yes  2.09 (1.39-3.14) ≤0.001 1.98 (0.78-5.01) 0,152 
Arthritis       No  1   1   
  Yes  1.20 (0.94-1.54) 0,138 2.06 (1.05-4.05) 0,035 
COPD/asthma      No  1   1   
                                  Yes  0.95 (0.67-1.35) 0,770 1.34 (0.61-2.94) 0,474 
Smoking Never  1   1   
  Current smoker  1.45 (0.96-2.18) 0,079 3.81 (1.39-10.45) 0,010 
  Past smoker  1.09 (0.84-1.39) 0,524 1.30 (0.62-2.73) 0,486 
Alcohol consumption   No  1   1   
  Yes  0.78 (0.60-1.00) 0,051 0.83 (0.42-1.66) 0,602 
BMI<18.5 and >30)          No  1   1   
                      Yes  1.32 (1.03-1.69) 0,027 1.41 (0.70-2.84) 0,334 
Disability ADL        None  1   1   
  ≥1 ADL  2.21 (1.43-3.44) ≤0.001 4.10 (1.84-9.12) ≤0.001
  ≥1 IADL  2.16 (1.00-4.67) 0,050 7.08 (2.12-23.62) ≤0.001
Self-rated health 
Excellent\Very 
good\Good  1   1   
  Fair\Poor  2.53 (1.63-3.93) ≤0.001 11.88 (5.51-25.62) ≤0.001
Loneliness    None of the time  1   1   
                All or most of the time  0.87 (0.51-1.50) 0,624 0.81 (0.29-2.26) 0,690 
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